ArticleHuman vaccines & immunotherapeutics2024

Immunogenicity, safety and reactogenicity of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 to 75 years: A comparison of phase 2b and phase 3 clinical trial material.

Archana Jastorff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.